Core Viewpoint - The company, Xinlitai, has received approval from the National Medical Products Administration for clinical trials of its innovative small molecule drug SAL0139 for the treatment of hyperlipidemia [1] Group 1 - The clinical trial approval notification was issued on November 21 [1] - SAL0139 is identified by the project code SAL0139 [1] - The drug is aimed at treating hyperlipidemia, a condition characterized by high levels of lipids in the blood [1]